Complement Therapeutics operates as a preclinical stage company. Complement Therapeutics develops a precision medicine diagnostic platform allowing it to stratify patients based on their complement-activation profile with the potential to enable both patient selection and serving as an efficacy biomarker in future clinical studies.
Perfuze is a medical device company based in Galway, Ireland, founded in 2018 by Wayne Allen and Liam Mullins. Specializing in innovative catheter technology, Perfuze aims to treat acute ischemic stroke, a condition that can lead to severe health complications if not addressed promptly. The company’s technology is designed to improve clinical outcomes while reducing procedural times, making the treatment safer and more cost-effective for patients. With over 30 years of combined experience in the medtech industry, the founders are focused on developing solutions that minimize the need for alternative treatment options during procedures. Perfuze is currently located in the Business Innovation Centre at the National University of Ireland, Galway, and is in the process of relocating to the IDA Business Park in Dangan, Galway.
Horama SAS is a biotechnology company based in Paris, France, established in 2014. It specializes in developing gene therapy products aimed at treating rare ophthalmic diseases, particularly targeting inherited retinal dystrophies and retinopathies. By utilizing recombinant adeno-associated viral vectors, Horama's therapies aim to deliver a functional copy of mutated genes to affected retinal cells. This approach seeks to restore normal cell function, prevent further deterioration of vision, and ultimately improve or restore visual capabilities for patients. The company is positioning itself as a significant player in the ophthalmic gene therapy sector, with the goal of enhancing patient autonomy while also contributing to reduced healthcare costs.
Developer of a medical system designed to advance smoke evacuation and insufflation technologies for laparoscopic, endoluminal, endoscopic, colorectal, and robotic surgery. The company's system maintains a smooth surgical workflow that seamlessly integrates with existing systems and products and protects the operating room staff from potential hazards of surgical smoke and aerosolized viruses, enabling hospitals to develop an optimal solution for smoke evacuation and insufflation.
Quanta is a medical devices company that develops advanced haemodialysis systems for use in the home and clinic. Quanta is focused on the commercialisation and ongoing development of SC+, an innovative cartridge-based haemodialysis system. SC+ is a high performance, compact haemodialysis system providing clinical efficacy by utilising typical flow rates of traditional in-centre machines. SC+ supports the entire ‘Continuum of Care’ for dialysis patients, from nurse-assisted treatment through self-care in centre to home haemodialysis. Their system facilitates the seamless transition between treatment modalities providing the best tool to enable flexibility for patients, and treatment options for physicians.
Atlantic Therapeutics is a medical technology company that develops pelvic floor muscle strengthening and nerve stimulation products.
The company's devices focus on the treatment of all types of incontinence, sexual health dysfunctions, and other associated disorders by strengthening muscles and modulating nerves of the pelvic floor, enabling bladder patients to treat their conditions associated with pelvic floor weakness. Its products are backed by strong clinical evidence and subjected to controlled trials.
It was established in Galway, Galway in 2013.
Shorla Pharma Limited is an Irish specialty pharmaceutical company focused on developing and manufacturing oncology drugs specifically for orphan and pediatric cancers. Founded in 2017 and headquartered in Clonmel, Ireland, with an additional office in New York, the company aims to provide accessible and affordable life-saving treatments. Its product portfolio includes SH-111, a sterile injectable solution for treating T-cell leukemia in both pediatric and adult patients, and SH-105, another oncology drug targeting rare forms of ovarian and pediatric cancer. Shorla Pharma is dedicated to addressing significant unmet needs in the oncology space, facilitating healthcare institutions in administering effective treatments for challenging cancer cases.
Quanta is a medical devices company that develops advanced haemodialysis systems for use in the home and clinic. Quanta is focused on the commercialisation and ongoing development of SC+, an innovative cartridge-based haemodialysis system. SC+ is a high performance, compact haemodialysis system providing clinical efficacy by utilising typical flow rates of traditional in-centre machines. SC+ supports the entire ‘Continuum of Care’ for dialysis patients, from nurse-assisted treatment through self-care in centre to home haemodialysis. Their system facilitates the seamless transition between treatment modalities providing the best tool to enable flexibility for patients, and treatment options for physicians.
STORM Therapeutics Limited is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing small molecule drugs that target RNA-modifying enzymes for cancer treatment and other immune diseases. Founded in 2015 and formerly known as Iceni Therapeutics Limited, the company utilizes a drug discovery and RNA analytics platform to identify novel targets and first-in-class drug candidates. By modulating RNA-modifying enzymes, STORM Therapeutics aims to address a range of diseases, including oncology, inflammation, viral infections, and central nervous system disorders. The company's innovative approach seeks to provide physicians with effective therapies targeting RNA epigenetic mechanisms.
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company is also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it is progressing its earlier-stage product candidate, FPI-1966 into clinical development for the treatment of head and neck, and bladder cancers expressing fibroblast growth factor receptor. The company was founded in 2014 and is headquartered in Hamilton, Canada.
PQ Bypass, Inc. is a medical device company based in Milpitas, California, focused on developing innovative solutions for peripheral vascular disease through minimally-invasive techniques. Founded in 2009, PQ Bypass specializes in products designed for the treatment of long-segment femoropopliteal disease, including the DETOUR System, PQ Snare, PQ Crossing Device, and TORUS Stent Graft System. The company aims to transform the treatment landscape for peripheral artery disease by providing effective endovascular options. Its leadership team comprises experienced professionals with backgrounds in major medical device firms and successful startups, bringing a wealth of expertise to the development of its advanced medical technologies.
Atlantic Therapeutics is a medical technology company that develops pelvic floor muscle strengthening and nerve stimulation products.
The company's devices focus on the treatment of all types of incontinence, sexual health dysfunctions, and other associated disorders by strengthening muscles and modulating nerves of the pelvic floor, enabling bladder patients to treat their conditions associated with pelvic floor weakness. Its products are backed by strong clinical evidence and subjected to controlled trials.
It was established in Galway, Galway in 2013.
Endotronix Inc. is a developer of advanced hemodynamic monitoring technologies focused on early detection of worsening heart failure. Founded in 2007 and based in Lisle, Illinois, the company specializes in miniaturized, wireless, and implantable pressure sensors that are utilized in interventional cardiovascular procedures. These sensors connect to an external measurement device and are part of a comprehensive platform that includes cloud-based disease management and outpatient hemodynamic management. Endotronix's innovative tools facilitate patient management by linking patients, clinicians, and reimbursement teams, ultimately enhancing clinical and economic outcomes. The company's technology aims to improve proactive heart management and empower health professionals to monitor patients' conditions effectively from home.
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company is also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it is progressing its earlier-stage product candidate, FPI-1966 into clinical development for the treatment of head and neck, and bladder cancers expressing fibroblast growth factor receptor. The company was founded in 2014 and is headquartered in Hamilton, Canada.
Medlumics S.L. designs and manufactures catheter based systems for the treatment of supra ventricular tachycardias. The company develops integrated photonic devices using optical coherence tomography technology, a light based diagnostic technique to provide sectional information about tissue. Medlumics S.L. was founded in 2009 and is based in Tres Cantos, Spain.
Atlantic Therapeutics is a medical technology company that develops pelvic floor muscle strengthening and nerve stimulation products.
The company's devices focus on the treatment of all types of incontinence, sexual health dysfunctions, and other associated disorders by strengthening muscles and modulating nerves of the pelvic floor, enabling bladder patients to treat their conditions associated with pelvic floor weakness. Its products are backed by strong clinical evidence and subjected to controlled trials.
It was established in Galway, Galway in 2013.
Prexton Therapeutics is a Swiss-based biopharmaceutical company, founded in 2012 by Francois Conquet and MS Ventures as part of the Merck Serono Entrepreneur Partnership Program, a facility to support the creation of spin-offs from Merck Serono. Prexton Therapeutics applies a new scientific approach that fully integrates molecular, behavioural and chemistry technologies to address Parkinson’s disease and other brain disorders. Prexton Therapeutics uses its powerful discovery platform to target specific novel compounds focused on the treatment of Parkinson’s disease.
Veryan was formed in 2003 as the result of a technology spin out from Imperial College, London, UK. Veryan has designed, patented and developed a highly innovative three dimensional (3D) Nitinol (nickel-titanium alloy) stent technology – BioMimics 3D – based on the pioneering work by Professor Colin Caro (Emeritus Professor of Physiological Mechanics, Dept. of Bioengineering, Imperial College London) on the link between vessel geometry, blood flow mechanics and vascular disease.
Quanta is a medical devices company that develops advanced haemodialysis systems for use in the home and clinic. Quanta is focused on the commercialisation and ongoing development of SC+, an innovative cartridge-based haemodialysis system. SC+ is a high performance, compact haemodialysis system providing clinical efficacy by utilising typical flow rates of traditional in-centre machines. SC+ supports the entire ‘Continuum of Care’ for dialysis patients, from nurse-assisted treatment through self-care in centre to home haemodialysis. Their system facilitates the seamless transition between treatment modalities providing the best tool to enable flexibility for patients, and treatment options for physicians.
Heart Metabolics Limited is focused on developing a pharmaceutical therapy for hypertrophic cardiomyopathy (HCM), a condition characterized by the thickening of the heart muscle, which can lead to heart failure and sudden death. With over 100,000 cases in the United States, HCM often presents more severely in younger individuals, particularly athletes. While existing cardiovascular drugs offer some relief, many patients do not benefit from current treatments. Heart Metabolics is advancing perhexiline, a drug already approved in Australia and New Zealand for angina, as a potential therapy for all forms of HCM. Following encouraging results from phase II clinical trials, the company is preparing to conduct further clinical trials in the U.S. and aims to obtain FDA approval for perhexiline as an orphan drug, a designation it already holds. Through this development, Heart Metabolics seeks to address significant unmet medical needs in HCM treatment.
Apica Cardiovascular is a pre-revenue medical device company focused on a novel technology for accessing and closing the heart's apex and the peripheral vascular system. This technology facilitates the delivery of large therapeutic devices, such as transcatheter heart valves and devices used in aortic aneurysm repair and left ventricular assist device implantation, through minimally invasive surgical or percutaneous approaches. By standardizing access and closure techniques, the technology aims to minimize blood loss during procedures on a beating heart. Having successfully demonstrated its initial concept in animal and cadaver models, Apica Cardiovascular is now preparing to advance to initial clinical trials.
Covagen is a biopharmaceutical company that specializes in developing bispecific FynomAbs, which are created by genetically fusing human Fynomer binding proteins to antibodies. This innovative approach results in therapeutics with unique modes of action and improved efficacy for treating inflammatory diseases and cancer. Covagen's lead product, COVA322, targets inflammatory conditions such as rheumatoid arthritis and psoriatic arthritis. The company's proprietary platform allows for the customization of FynomAbs by attaching Fynomers at multiple sites on an antibody, enabling tailored therapeutic architectures. Founded in 2007 as a spin-off from ETH Zurich, Covagen has established strategic partnerships, including a collaboration with Mitsubishi Tanabe for developing bispecific FynomAbs against specific target pairs. The company is backed by a consortium of investors, which includes notable names in the life sciences sector.
Biosensia is a Point-of-Care in-vitro diagnostics company that has a novel point-of-care platform, RapiPlex, available for licensing.
RapiPlex combines highly innovative technologies to produce a practical, rapid, multiplexing POC in-vitro diagnostics (IVD) platform, enabling access to a broad range of diagnostic applications.
Its component chip and cartridge system are compatible with a variety of common biological sample types, including whole blood, serum, saliva, urine and nasal/genital swabs.
Veryan was formed in 2003 as the result of a technology spin out from Imperial College, London, UK. Veryan has designed, patented and developed a highly innovative three dimensional (3D) Nitinol (nickel-titanium alloy) stent technology – BioMimics 3D – based on the pioneering work by Professor Colin Caro (Emeritus Professor of Physiological Mechanics, Dept. of Bioengineering, Imperial College London) on the link between vessel geometry, blood flow mechanics and vascular disease.
Novate Medical Technologies is a medical device development company based in New Orleans that focuses on creating affordable and sustainable medical products to meet critical global health needs. The company's flagship product, InfaClip, is a patented disposable obstetric device designed to simultaneously cut, clamp, and shield the infant, mother, and birthing attendant from infection. This innovation aims to reduce maternal and neonatal mortality rates, particularly in developing countries, by providing healthcare professionals with a tool that captures clots and prevents them from reaching the lungs. Through its efforts, Novate Medical addresses significant healthcare challenges while promoting safety and efficiency in obstetric care.
Provesica is a Cambridge-based biopharmaceutical company specialising in overactive bladder. The Company’s development compound, XEN-D0501, is highly potent antagonist of the vanilloid receptor, TRPV1, and is about to start Phase 2 clinical development. In addition to XEN-D0501, Provesica owns a portfolio of intellectual property covering diverse TRPV1 antagonists suitable for development in overactive bladder or other indications where TRPV1 has been validated as an intervention target. Provesica was established in 2010 following the demerger of the overactive bladder and TRPV1 interests of Xention Ltd, an ion channel specialist drug discovery and development company. Provesica has so far raised £4 million in finance to progress its lead programme through Phase 2 development.
Covagen is a biopharmaceutical company that specializes in developing bispecific FynomAbs, which are created by genetically fusing human Fynomer binding proteins to antibodies. This innovative approach results in therapeutics with unique modes of action and improved efficacy for treating inflammatory diseases and cancer. Covagen's lead product, COVA322, targets inflammatory conditions such as rheumatoid arthritis and psoriatic arthritis. The company's proprietary platform allows for the customization of FynomAbs by attaching Fynomers at multiple sites on an antibody, enabling tailored therapeutic architectures. Founded in 2007 as a spin-off from ETH Zurich, Covagen has established strategic partnerships, including a collaboration with Mitsubishi Tanabe for developing bispecific FynomAbs against specific target pairs. The company is backed by a consortium of investors, which includes notable names in the life sciences sector.
Veryan was formed in 2003 as the result of a technology spin out from Imperial College, London, UK. Veryan has designed, patented and developed a highly innovative three dimensional (3D) Nitinol (nickel-titanium alloy) stent technology – BioMimics 3D – based on the pioneering work by Professor Colin Caro (Emeritus Professor of Physiological Mechanics, Dept. of Bioengineering, Imperial College London) on the link between vessel geometry, blood flow mechanics and vascular disease.
Quanta is a medical devices company that develops advanced haemodialysis systems for use in the home and clinic. Quanta is focused on the commercialisation and ongoing development of SC+, an innovative cartridge-based haemodialysis system. SC+ is a high performance, compact haemodialysis system providing clinical efficacy by utilising typical flow rates of traditional in-centre machines. SC+ supports the entire ‘Continuum of Care’ for dialysis patients, from nurse-assisted treatment through self-care in centre to home haemodialysis. Their system facilitates the seamless transition between treatment modalities providing the best tool to enable flexibility for patients, and treatment options for physicians.
Opsona Therapeutics is a drug development firm based in Dublin, Ireland, specializing in innovative approaches to immunology. Founded in 2004, the company focuses on developing novel therapeutic strategies that target the innate immune system, which plays a crucial role in various major human diseases. These include autoimmune and inflammatory diseases, cancer, transplant rejection, diabetes, Alzheimer's disease, and atherosclerosis. By modulating the human innate immune response, Opsona aims to create new drug candidates that can significantly improve treatment outcomes for patients facing these challenging health issues.
Opsona Therapeutics is a drug development firm based in Dublin, Ireland, specializing in innovative approaches to immunology. Founded in 2004, the company focuses on developing novel therapeutic strategies that target the innate immune system, which plays a crucial role in various major human diseases. These include autoimmune and inflammatory diseases, cancer, transplant rejection, diabetes, Alzheimer's disease, and atherosclerosis. By modulating the human innate immune response, Opsona aims to create new drug candidates that can significantly improve treatment outcomes for patients facing these challenging health issues.
Biosensia is a Point-of-Care in-vitro diagnostics company that has a novel point-of-care platform, RapiPlex, available for licensing.
RapiPlex combines highly innovative technologies to produce a practical, rapid, multiplexing POC in-vitro diagnostics (IVD) platform, enabling access to a broad range of diagnostic applications.
Its component chip and cartridge system are compatible with a variety of common biological sample types, including whole blood, serum, saliva, urine and nasal/genital swabs.
TriMed Research, Inc. engages in the research and development of therapeutic products primarily related to mammary gland protein designated as MAA.
Diabetica Ltd was established in September 2004 to commercialise discoveries at the Diabetes Research Group in the University of Ulster, under the leadership of scientific co-founders Prof Peter Flatt, Dr Neville McClenaghan and Prof Finbarr O'Harte.
Opsona Therapeutics is a drug development firm based in Dublin, Ireland, specializing in innovative approaches to immunology. Founded in 2004, the company focuses on developing novel therapeutic strategies that target the innate immune system, which plays a crucial role in various major human diseases. These include autoimmune and inflammatory diseases, cancer, transplant rejection, diabetes, Alzheimer's disease, and atherosclerosis. By modulating the human innate immune response, Opsona aims to create new drug candidates that can significantly improve treatment outcomes for patients facing these challenging health issues.